

# **PCT**

REC'D	2 8 FEB 2005
WiPO	PCT
TTW	


## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference		DOTTON A 1416							
<del>77 -</del>	FOR FURTHER ACTION See Form PCT/IPEA/416								
100871-1 SE International application No.	International filing date (day/mo	onth/year) Priority date (day/month/year)							
PCT/SE2003/001602	15.10.2003	18.10.2002							
C07D 401/12	International Patent Classification (IPC) or national classification and IPC								
CO/D 101/12	CO7D 401/12								
<u> </u>									
Applicant									
AstraZeneca AB et al									
This report is the international property under Article 35 and to	<ol> <li>This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</li> </ol>								
2. This REPORT consists of a total		nding this cover sheet.							
3. This report is also accompanied l	by ANNEXES, comprising:								
	at and to the International Bureau	a total of 3 sheets, as follows:							
	1	inco which have been amended and are the basis of this report							
and/or sheet	s containing rectifications author	ized by this Authority (see Rule 70.16 and Section 607 of the							
The street artists	ive Instructions).	nich this Authority considers contain an amendment that goes							
beyond the	disclosure in the international app	plication as filed, as indicated in item 4 of Box No. I and the							
Supplement	· ·								
b (sent to the Internat	tional Bureau only) a total of (ind	licate type and number of electronic carrier(s))							
Jabla Sama colty	, containing a s	sequence listing and/or tables related thereto, in computer I Box Relating to Sequence Listing (see Section 802 of the							
Administrative Inst	ructions).								
4. This report contains indications	relating to the following items:	i							
	of the report								
Box No. II Priori		·							
Box No. III Non-	establishment of opinion with reg	gard to novelty, inventive step and industrial applicability							
, 20,21,0,2	of unity of invention								
Box No. V Reas	oned statement under Article 35(2 cability; citations and explanation	with regard to novelty, inventive step or industrial    supporting such statement							
Box No. VI Certa	in documents cited								
Box No. VII Certa	ain defects in the international app	plication							
Box No. VIII Certs	ain observations on the internation	in observations on the international application							
Date of submission of the demand		Date of completion of this report							
		0.00.0005							
30.04.2004		2.02.2005							
Name and mailing address of the IPEA		nthorized officer							
Patent- och registreringsverk Box 5055		Cámor Tagorlöf/RG							
S-102 42 STOCKHOLM	1_	arolina Gómez Lagerlöf/BS elephone No. +46 8 782 25 00							
Facsimile No. +46 8 667 72 8	0								





Box	k No. I	Bas	sis of the report				
1.	<ol> <li>With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.</li> </ol>						
		This report is based on a translation from the original language into the following language, which is the language of a translation furnished for the purposes of:					
		П	international search (under Rules 12.3 and 23.1(b))	1			
	•	П	publication of the international application (under Rule 12.4)	- [			
			international preliminary examination (under Rules 55.2 and/or 55.3)				
2.	furnisi	With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):					
			ernational application as originally filed/furnished	1			
	$\boxtimes$		scription:				
			1-9 as originally filed/form				
		pages*					
	K 7	pages*		—			
	$\boxtimes$	the clai					
		pages					
		pages*	10 12 07 12 2004	ucie 19			
1		pages*					
			awings:	niched			
		pages pages*	+				
1		pages*	<del></del>	·			
			nence listing and/or any related table(s) — see Supplemental Box Relating to Sequence Listing.				
3.	Ш.	t ne an	mendments have resulted in the cancellation of:				
			the description, pages				
ļ	•		the claims, Nos.				
		$\Box$	the drawings, sheets/figs				
		$\sqcap$	the sequence listing (specify):	•			
			any table(s) related to the sequence listing (specify):				
4.		This made,	report has been established as if (some of) the amendments annexed to this report and listed below had, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental I.c.)).	not been Box (Rule			
ı			the description, pages				
			the claims, Nos.				
		$\Box$	the drawings, sheets/figs	-			
ì		一					
			the sequence listing (specify):  any table(s) related to the sequence listing (specify):				
*	If iter	n 4 appli	lies, some or all of those sheets may be marked "superseded."				

Form PCT/IPEA/409 (Box No. I) (January 2004)

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

In the fional application No.

PCT/SE2003/001602

Box No. V	Reasoned statement u citations and explanat		5(2) with regard to novelty, inventive step or industrial applicability ng such statement	y; 	
1. Statement	<b>:</b>				
Nove	lty (N)	Claims Claims	1-14	YES NO	
Inven	ative step (IS)	Claims Claims	1-14	YES NO	
Indus	trial applicability (IA)	Claims Claims	1-14	YES NO	
2. Citations and explanations (Rule 70.7) The claims relate to a process for production of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)-methyl]-thio]-1H-benzimidazole. During the search the following document were found: A WO 9722603 Document A shows a similar process for production of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)-methyl]-thio]-1H-benzimidazole.					

The document shows the general state of the art.

Thus, claims 1-14 are considered to fulfil the requirements of novelty, inventive step and industrial applicability.

WO 2004/035565

PCT/SE2003/001602

10

### CLAIMS.

5

10

1. A process for the manufacture of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]-thio]-1<u>H</u>-benzimidazole of formula I

$$s \rightarrow N$$

from (4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl alcohol comprising the following reaction steps carried out in a consecutive order in one main solvent system without isolation of the intermediates formed during the process

### Step 1:

reacting (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl alcohol (pyrmethyl alcohol) of the formula Ia

with a chloro-dehydroxylating agent, providing (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl chloride (pyrmethyl chloride) of the formula ib

20

15

WO 2004/035565

PCT/SE2003/001602

11

Step 2:

5

**25** 

reacting (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl chloride of the formula Ib, prepared in Step 1 above, with 2-mercapto-5-methoxybenzimidazole (metmercazole) of the formula Ic

in the presence of a base, providing 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole (pyrmetazole) of the formula I c h a r a c t e r i z e d in that the solvent system, common for the whole reaction sequence, comprises water immiscible organic solvent with a specified amount of between 0.3 and 5.5 mg water / ml water immiscible organic solvent added.

- 2. A process according to claim 1 wherein the water immiscible organic solvent is toluene.
  - 3. A process according to claim 1 wherein the water immiscible organic solvent is ethyl acetate.
- 4. A process according to claim 1, characterized in that the specified amount of water is present from the start of the reaction according to Step 1.
  - 5. A process according to any one of claims 1 and 4, characterized in that the specified amount of water is added during the charging of the chloro-dehydroxylating agent in the reaction according to Step 1.

AMENDED SHEET

BEST AVAILABLE COPY

WO 2004/035565

PCT/SE2003/001602

12

- 6. A process according to any one of claims 1 to 5, characterized in that the specified amount of water is added after charging of the chloro-dehydroxylating agent in the reaction according to Step 1.
- 7. A process according to claim 1, characterized in that the specified amount of water is 0.3 5.0 mg/ml of water immiscible organic solvent.
  - 8. A process according to claim 1, characterized in that the specified amount of water is 0.4 2.4 mg/ml of water immiscible organic solvent.
  - 9. A process according to claim 1, characterized in that the specified amount of water is 1.0-2.4 mg/ml of water immiscible organic solvent.
- 10. A process according to any one of claims 1 to 9, characterized in that the reaction according to Step 1 is carried out at a temperature between -5°C and +45°C.
  - 11. A process according to any one of claims 1 to 9, characterized in that the temperature is between -5°C and +35°C.
- 20 12. A process according to any one of claims 1 to 9, characterized in that the temperature is between +10°C and +35°C.
  - 13. A process according to any one of claims 1 to 9, characterized in that the temperature is between +25°C and +35°C.
  - 14. A process according to any one of claims 1 to 13, characterized in that the chloro-dehydroxylating agent is thionyl chloride.

30

25

.10